DYSTONIA TREATMENT BY BOTULINUM TOXINS

肉毒杆菌毒素治疗肌张力障碍

• 批准号: 3265589
• 负责人: ALAN B SCOTT
• 金额: $ 11.87万
• 依托单位: SMITH-KETTLEWELL EYE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-12-01 至 1993-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3265589
• 关键词: botulinum toxins; cell type; combination chemotherapy; cross immunity; drug adverse effect; drug design /synthesis /production; drug interactions; drug resistance; drug screening /evaluation; dystonia; electromyography; eyelids; immune tolerance /unresponsiveness; immunization; immunotherapy; laboratory mouse; laboratory rabbit; neuromuscular disorder chemotherapy; paralysis; tissue /cell culture

DESCRIPTION: (Principal Investigator's Abstract) Botulinum A toxin has emerged as a useful drug for treatment of focal dystonias. The major problems with this approach are so that some patients develop antibodies to the drug, and almost all would like to see it last longer after each injection. In this project we will develop and test in animals and humans the effect of botulinum toxins B, D, E and F on eyelid and extraocular muscle function, to determine: 1) if patients who have become resistant to type A botulinum toxin can be helped by other types; 2) if these toxins have different effects than the currently used type A toxin; 3) if toxins are synergistic when used together, having either greater effect or greater duration of action than when used singly; 4) if combinations of toxins are less antigenic than individual toxins.

描述：(主要研究人员摘要)A型肉毒杆菌毒素 成为治疗局限性肌张力障碍的有效药物。少校 这种方法的问题是，一些患者会产生抗体 这种药物，几乎所有人都希望在每次服用后都能持续更长时间 注射。在这个项目中，我们将在动物和人类身上进行开发和测试 肉毒杆菌毒素B、D、E、F对眼睑和眼外的影响 肌肉功能，以确定： 1)如果对A型肉毒毒素产生抗药性的患者 其他类型的帮助； 2)如果这些毒素与目前使用的A型毒素有不同的影响 毒素； 3)如果毒素在一起使用时具有协同作用，则具有更大的 与单独使用时相比，有效或持续时间更长； 4)如果组合毒素的抗原性低于单个毒素。